Volume : 13, Issue : 04, April – 2026
Title:
FORMULATION AND EVALUATION OF DEXAMETHASONE NIOSOMAL IN-SITU GEL FOR EFFECTIVE OCULAR DRUG DELIVERY
Authors :
Y. Sarah Sujitha *, Cherlopalli Sandhya
Abstract :
The purpose of this study was to formulation and evaluation of Dexamethasone niosomal in-situ gel for effective ocular drug delivery. Dexamethasone niosomal in-situ gel, was prepared Ethanol injection and Thin film hydration technique method. Results: The particle size (average) was 2002.32nm. The DM powder being amorphous in nature was found to possess small particle size. Vesicle size of niosomes was in 0.2-0.5 μm range. The vesicles were circular in shape with uniform vesicle size distribution. The zeta value of niosomes after incorporation of drug was -44mV indicating that the stability was not affected High zeta value irrespective of charge that is positive or negative, will cause the suspended particles to repel each oher thus preventing coagulation or aggregate formation process.
Key words: Niosomal in-situ gel, Ethanol injection method & Fourier transform infrared spectroscopy.
Cite This Article:
Please cite this article in press Y. Sarah Sujitha et al., Formulation And Evaluation Of Dexamethasone Niosomal In-Situ Gel For Effective Ocular Drug Delivery., Indo Am. J. P. Sci, 2026; 13(04).
REFERENCES:
1. Mayol, L, Quaglia F, Borzacchiello A, Ambrosio L, La Rotonda MI. A novel poloxamers/hyaluronic acid in situ forming hydrogel for drug delivery: rheological, mucoadhesive and in vitro release properties. Eur. J. Pharm. Biopharm. 2008; 70:199- 206.
2. Vodithala, S, Khatry S, Shastri N, Sadanandam M. Development and evaluation of thermoreversible ocular gels of ketorolac tromethamine. Int. J. Biopharm.2010;1: 39-45.
3. Darwhekar G, Jain P, Jain DK, Agrawal G, Development and optimization of dorzolamide hydrochloride and timolol maleate in situ gel for glaucoma treatment. Asian J. Pharm. Anal.2011; 1: 93-97.
4. Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int. J. Pharm.2001; 229(1-2):29-36.
5. Kanoujia J, Sonker K, Pandey H, Kymonil KM, Saraf SA. Formulation and characterization of a novel pH-triggered in-situ gelling ocular system containing Gatifloxacin, Int. Curr. Pharm. J 2012; 1(3): 43-49.
6. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Nanoparticles laden in situ gel for sustained ocular drug delivery. J Pharm Bioall Sci 2013; 5(2): 162-65.
7. Song J, Bi H, Xi X, Guo J, Wang X, Liu D. Preparation and evaluation of sinomenine hydrochloride in situ gel for uveitis treatment. Int Immunopharmacol 2013; 17(1): 99- 107.
8. Geethalakshmia A, Karkib R, Sagib P, Kumar S, Venkatesh.D. Temperature Triggered In situ Gelling System for Betaxolol in Glaucoma, J. Appl. Pharm. Sci. 2013; 3(02):153- 59.
9. Gaikwad V, Gujar V, K Pratyusha Rao, Chaudhari P, Formulation and evaluation of niososmal in situ gel for ophthalmic use, Am. J. PharmTech Res. 2012; 2(6):864-82.
10. Lavanya B, Indira S, Srinivas P, Formulation and evaluation of ocular niosomal in situ gels of linezolid, IJPSR, 2014; 5(4): 1367-75.
11. Shastri DH, Prajapati ST, Patel LD. Thermoreversible mucoadhesive ophthalmic in situ hydrogel: design and optimization using a combination of polymers. Acta Pharm. 2010; 60(3): 349-60.
12. Balasubramaniam J, Kant S, Pandit JK. In vitro and in vivo evaluation of the Gelrite1 gellan gum-based ocular delivery system for indomethacin. Acta Pharm. 2003; 53 (4): 251-61.
13. Tayel SA, El-Nabarawi MA, Tadros MI, Abd-Elsalam WH. Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits. Int. J. Pharm. 2013; 443: 293-305.
14. El Sayeh FA, Ela A, El Khatib MM, Formulation and evaluation of new long acting metoprolol tartrate ophthalmic gels, Saudi Pharm J. 2014;22(6): 555-63.
15. Farheen T, Shahi SR, Shaikh AM, Zudbuke N, Ali SA. Formulation development and evaluation of in situ ophthalmic gel of sodium cromoglycate, Der Pharmacia Sinica, 2013; 4(2): 109-18.
16. Kaur IP, Smitha R. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm. 2002; 28(4): 353–69.
17. Sharma P, Dua K, Sharma VK, Sara UVS, Yadav VP, Samad A, Prajapati S, Ophathalmic drug delivery system, The Indian Pharmacist, 2008; 76.
18. Zignani M, Tabatabay C, Gurny R. Topical semi-solid drug delivery: kinetics and tolerance of ophthalmic hydrogels. Adv. Drug Deliv. Rev. 1995; 16: 51–60.
19. Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev. 2010; 62(1): 83–99.